Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated h...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Infect Drug Resist
Auteurs principaux: Toh, Zheng Quan, Kosasih, Jennie, Russell, Fiona M, Garland, Suzanne M, Mulholland, Edward K, Licciardi, Paul V
Format: Artigo
Langue:Inglês
Publié: Dove 2019
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6613616/
https://ncbi.nlm.nih.gov/pubmed/31308715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S178381
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires